四君子汤加减辅助化疗治疗结直肠癌晚期临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.3

基金项目:


Clinical Study on Modified Sijunzi Tang Combined with Chemotherapy for Advanced Colorectal Cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察四君子汤加减辅助化疗治疗结直肠癌晚期的临床效果。方法:回顾性选取88 例结直肠癌晚期患者,根据不同治疗方式分成观察组和对照组各44 例。对照组给予化疗治疗,观察组在对照组基础上予以四君子汤加减治疗。比较2 组中医证候积分、血管内皮生长因子(VEGF)、基质金属蛋白酶-2 (MMP-2)、T 细胞亚群(CD3+、CD4+、CD8+) 水平变化,观察2 组治疗期间不良反应情况。结果:治疗前,2 组腹胀、神疲、纳呆、便溏各项评分以及总评分比较,差异无统计学意义(P>0.05)。治疗后,2 组各项症状评分以及总评分均较治疗前降低,且观察组各项症状评分以及总评分均低于对照组,差异有统计学意义(P<0.05)。治疗前,2 组MMP-2、VEGF、T 淋巴细胞亚群(CD3+、CD4+、CD8+) 水平比较,差异无统计学意义(P>0.05)。治疗后,2 组MMP-2、VEGF 水平低于治疗前(P<0.05);观察组MMP-2、VEGF、CD8+水平低于对照组,CD3+、CD4+水平高于对照组(P<0.05)。观察组胃肠道反应、肝肾功能损伤、白细胞减少以及血小板减少发生率分别为13.6%、9.1%、20.5%、6.8%,均低于对照组的31.8%、29.5%、45.5%、27.3%,差异有统计学意义(P<0.05)。结论:在结直肠癌晚期化疗患者中应用四君子汤加减治疗能够减轻患者临床症状,降低MMP-2、VEGF 水平,调节患者免疫功能。

    Abstract:

    Abstract:Objective:To observe the clinical effect of modified Sijunzi tang combined with chemotherapy on advanced colorectal cancer. Methods:A total of 88 patients with advanced colorectal cancer were retrospectively selected and divided into the observation group and the control group according to different treatment methods,with 44 cases in each group. The control group was treated with chemotherapy,and the observation group was additionally treated with modified Sijunzi tang based on the treatment of the control group. The changes of Chinese medicine syndrome score,vascular endothelial growth factor(VEGF),matrix metalloproteinase-2(MMP-2) and T cell subsets(CD3+,CD4+,CD8+) were compared between the two groups, and the adverse reactions during treatment were observed. Results: Before treatment, there was no significant difference in the comparison of the scores of abdominal distension, mental fatigue, poor appetite and thin and unformed stool as well as the total score between the two groups(P>0.05). After treatment,the symptom scores and total score in the two groups were decreased when compared with those before treatment,and the symptom scores and the total score in the observation group was lower than that in the control group, the difference being significant(P<0.05). Before treatment, there was no significant difference in the levels of MMP-2,VEGF and T lymphocyte subsets(CD3+,CD4+,CD8+ ) between the two groups(P>0.05). After treatment, the levels of MMP- 2 and VEGF in both groups were lower than those before treatment(P<0.05),and the levels of MMP-2,VEGF and CD8+ in the observation group were lower than that in the control group,CD3 + and CD4 + were higher than that in the control group(P<0.05).The incidence of gastrointestinal reaction,liver and kidney function injury, leucopenia and thrombocytopenia in the observation group were 13.6% , 9.1% , 20.5% and 6.8%,respectively,which were lower than those of 31.8%,29.5%,45.5% and 27.3% in the control group,differences being significant(P<0.05). Conclusion: Sijunzi tang can reduce clinical symptoms, decrease levels of serum MMP- 2 and VEGF,and regulate immune function in patients with advanced colorectal cancer chemotherapy.

    参考文献
    相似文献
    引证文献
引用本文

蔡佳吟,罗国庆,李爱平.四君子汤加减辅助化疗治疗结直肠癌晚期临床研究[J].新中医,2021,53(21):171-174

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-11-12
  • 出版日期: